M acrophages, which were originally identified by Metchnikoff on account of their phagocytic nature, are ancient cells in metazoan phylogeny. In adult mammals, they are found in all tissues where they display great anatomical and functional diversity. In tissues, they are organized in defined patterns with each cell occupying its own territory, a type of tissue within a tissue. Although several attempts have been made to classify macrophages, the most successful definition is the mononuclear phagocytic system (MPS), which encompasses these highly phagocytic cells (professional phagocytes) and their bone marrow progenitors. In the MPS schema, adult tissue macrophages are defined as end cells of the mononuclear phagocytic lineage derived from circulating monocytes that originate in the bone marrow. However, this definition is inadequate as macrophages have several origins during ontogeny and each of these different lineages persist into adulthood 1 . Other functional classifications of macrophages have included binary classifications that refer to inflammatory states. These include the activated macrophage and alternatively activated macrophage (AAM) categories, and the derivative M1 and M2 categories for these types of macrophage in the non-pathogen-driven condition 2, 3 . These two states are defined by responses to the cytokine interferon-c (IFN-c) and activation of Toll-like receptors (TLRs), and to interleukin-4 (IL-4) and IL-13, respectively. Although this classification is a useful heuristic that may reflect extreme states, such as that of activated macrophages during immune responses mediated by T helper cells that express IFN-c (T H 1) or of AAMs during parasitic infections 2 , such binary classifications cannot represent the complex in vivo environment for most macrophage types, in which numerous other cytokines and growth factors interact to define the final differentiated state. Indeed, transcriptional profiling of resident macrophages by the Immunological Genome Project show that these populations have high transcriptional diversity with minimal overlap, suggesting that there are many unique classes of macrophages 1 . Macrophages have roles in almost every aspect of an organism's biology; from development, homeostasis and repair, to immune responses to pathogens. Resident macrophages regulate tissue homeostasis by acting as sentinels and responding to changes in physiology as well as challenges from outside. During these homeostatic adaptations, macrophages of different phenotypes can also be recruited from the monocyte reservoirs of blood, spleen and bone marrow 4 , and perhaps from resident tissue progenitors or through local proliferation 5, 6 . Unfortunately, in many cases these homeostatic and reparative functions can be subverted by continuous insult, resulting in a causal association of macrophages with disease states, such as fibrosis, obesity and cancer (Fig. 1) . Thus, macrophages are an incredibly diverse set of cells that constantly shift their functional state to new metastable states ('set points') in response to changes in tissue physiology or environmental challenges. They should not even be considered as one cell type but should be subdivided into different functional subsets according to their different origins.
Macrophage responses to pathogens have been discussed previously 2, 7, 8 and therefore this Review focuses on the homeostatic mechanisms by which macrophages contribute to physiological and pathophysiological adaptations in mammals. Here we define the hallmarks of macrophages that perform particular functions, taking into account new insights into the diversity of their lineages, identity and regulation. This phenotypic diversity is essential to understand because macrophages are central to many disease states and have emerged as important therapeutic targets in many diseases.
Macrophage origins rewritten
Ontologically, the MPS has been proposed to arise from a rigid temporal succession of macrophage progenitors 9 . In mice, these start to develop first at embryonic day 8 from the primitive ectoderm of the yolk sac and give rise to macrophages that do not have a monocytic progenitor. This primitive system is followed by definitive haematopoiesis in the fetal liver, which is initially seeded by haematopoietic progenitors from the yolk sac and subsequently from the hematogenic endothelium of the aortogonadal-mesonephros region of the embryo. After this point, the fetal liver is the source of definitive haematopoiesis that generates circulating monocytes during embryogenesis. Coincident with the postnatal formation of bone, fetal liver haematopoiesis declines and is replaced by bone marrow haematopoiesis. This definitive haematopoiesis is the source of circulating monocytes (resident, lymphocyte antigen 6c negative (Ly6c 2 ) and inflammatory Ly6c 1 in mice) and from which it has been considered that all resident macrophages in tissues are derived 4 . However, this model for the formation of the MPS has been challenged (Fig. 2) . First, lineagetracing experiments have shown that microglia are primarily derived from the yolk-sac progenitors, whereas Langerhans cells have a mixed origin from yolk sac and fetal liver 10, 11 . Second, experiments using ablation of c-Myb-dependent bone marrow haematopoiesis followed by transplantation with genetically dissimilar bone marrow together with lineage tracing showed that the major tissue-resident population of macrophages (defined as F4/80 bright) in skin, spleen, pancreas, liver, brain and lung arise from yolk sac progenitors. In a few tissues, such as kidney and lung, macrophages have a chimaeric origin being derived from yolk sac (F4/80 high ) and bone marrow (F4/80 low ). In contrast to this yolk sac and fetal liver origin for most macrophages, classical dendritic cells and the F4/80 low macrophages are continuously replaced by bone-marrow-derived progenitors 6 . These data indicate that there are at least three lineages of macrophages in the mouse, which arise at different stages of development and persist to adulthood. The data also call into question the function of circulating monocytes because, at least in mice, these cells do not seed the majority of the adult tissues with macrophages. In fact, complete loss of CD16 1 monocytes in humans seems to be of little consequence 12 . Thus, the function of monocytes needs to be defined with the possibility that patrolling monocytes (Ly6c 2 ) act to maintain vessel integrity and to detect pathogens while inflammatory monocytes (Ly6c 1 ) are recruited predominantly to sites of infection or injury, or to tissues that have continuous cyclical recruitment of macrophages, such as the uterus.
Regardless of their origin, genetic and cell culture studies indicate that the major lineage regulator of almost all macrophages is macrophage colony-stimulating factor 1 receptor (CSF1R). This class III transmembrane tyrosine kinase receptor is expressed on most, if not all, mononuclear phagocytic cells, and a reporter mouse expressing green fluorescent protein (GFP) from the Csf1r locus illustrates their relative abundance (5-20% of cells) and tissue distribution 13 . Csf1r expression and its requirement for differentiation distinguish macrophages from many, but not all, dendritic-cell subtypes 14 . Targeted ablation of the Csf1r causes severe depletion of macrophages in many tissues, such as brain, skin, bone, testis and ovary. Moreover, an initial comparison of the Csf1r-null mice with those homozygous for a spontaneous (osteopetrotic (Csf1 op )) null mutation in its cognate ligand (Csf1 op/op mice) demonstrated that all phenotypes in the Csf1r-null mice were also found in the Csf1 op/op mice, indicating that CSF1 has only a single receptor 15 . However, the phenotype of the Csf1r-null mice is more severe than that of the Csf1-null mice, including the complete loss of microglia and Langerhans cells 10, 16 in the Csf1r-null mice, which suggested the presence of another ligand. Indeed, IL-34, with a distinct but overlapping pattern of expression with Csf1, was recently identified as an additional ligand for the CSF1R 17 . Targeted ablation of Il34 resulted in loss of microglia and Langerhans cells, but had little impact on bone marrow, liver or splenic macrophages 18 . Despite the importance of the CSF1R in macrophage specification, Csf1r-null mutant mice still have some tissue macrophages, such as in the spleen, indicating the existence of other macrophage growth factors. Potential candidates include granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-3, which act as macrophage growth factors in tissue culture. However, mice lacking GM-CSF or IL-3 do not show notable defects in their tissue macrophages, except in alveolar macrophages, which indicates that they are regulated by GM-CSF 19 . Vascular endothelium growth factor A (VEGFA) proteins are another candidate regulator of macrophages because they can compensate for the loss of Csf1 in osteoclast development in vivo 20 . In contrast to CSF1 that is found in all tissues and serum, and is a basal regulator of macrophage number through a negative feedback loop 15 , GM-CSF is not a steady-state ligand and seems to be synthesized in response to challenge 21 . GM-CSF and FLT3L regulate the maturation of dendritic cell populations with the notable exception of Langerhans cells, whose development is dependent on Csf1r
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. Recent genomic profiling of Langerhans cells place them closer to macrophages than dendritic cells, and this data together with 
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Figure 1 | Macrophages in development, homeostasis and disease.
Macrophages have many developmental roles in shaping the architecture of various tissues, such as brain, bone and mammary gland tissues. After development of the organism, macrophages modulate homeostasis and normal physiology through their regulation of diverse activities, including metabolism and neural connectivity, and by detecting damage. However, these trophic and regulatory roles are often subverted by continuous insult, and macrophages contribute to many diseases that are often associated with ageing. EAE, experimental autoimmune encephalomyelitis; IBD, inflammatory bowel disease. 23 . This functional heterogeneity probably results from the dynamic crosstalk between resident tissue macrophages and the client cells that they support. To understand this macrophage diversity there must be an understanding of transcriptional regulation. The most important of these transcription factors is SFPI1 (also known as PU.1), a member of the ETS family whose loss following targeted mutation results in complete depletion of CD11b 1 F4/80 1 macrophages, including those derived from the yolk sac 6 . However, Sfpi1 action is not limited to macrophages as B cells are also severely depleted in these Sfpi1-null mutant mice. Similarly, other members of the ETS family are also involved in macrophage differentiation, including Ets2, which positively regulates the Csf1r promoter. In adults, Mafb (also known as v-Maf) is required for the local proliferation that maintains resident macrophages 4 . In the differentiation of osteoclasts, Fos and Mitf are required 24 , whereas Gata2 is required for monocyte development but not for resident macrophage populations 25 . However, little is known about the transcriptional control of the differentiation of the diverse tissue macrophages, such as those in the liver and brain 13 . Most research has focused on their functional activation in response to environmental challenges 23 , as discussed below. Nevertheless, the recent transcriptional profiling of resident macrophages has identified many candidate transcription factors, including those that may regulate core macrophageassociated genes such as Mitf (micropthalmia) family members, Tcf3, Cebpa, Bach1, Creg1 and genes that are unique to subpopulations, including Gata6 and Spic, whose targeted gene ablation will undoubtedly define subsets of macrophages and their unique activities 
Macrophages in development
Metchnikoff proposed that macrophages participate in the maintenance of tissue integrity and homoeostasis. To do so, macrophages would need to be able to discriminate self from non-self, sense tissue damage and recognize invading pathogens, an insight that led to the concept of innate immunity for which he was awarded the Nobel prize. The inherent properties of macrophages, which include sensing inside from out, motility throughout the organism, phagocytosis and degradation, were later sequestered to instruct the acquired immune system as it evolved to more efficiently deal with changing pathogenic challenges. This enhanced sophistication of the immune system probably resulted in the evolution of dendritic cells as specialized mononuclear phagocytes to interface with the acquired immune system. Indeed, in mammals, dendritic cells seem to be focused on initiating tissue immune responses, whereas tissue macrophages seem to be focused on homeostasis and tissue integrity 9 . Emphasis on the immunological and repair aspects of macrophage function has overshadowed their importance in the development of many tissues; for example, studies of Csf1 op/op mice, which lack many macrophage populations, have revealed a cluster of developmental abnormalities 19 . Most notable among these is the development of osteopetrosis, which is caused by the loss of bone-reabsorbing macrophages known as osteoclasts. This phenotype, which is also observed in Sfpi1-null mice, is axiomatic for the roles of macrophages in development, in that cell fate decisions are unchanged but the tissue remodelling and expression of growth factors is lost. Specifically, although bone formation is intact in Csf1-or Spi1-null mice, the bones are not sculpted to form the cavities in which haematopoiesis commences 19 . Consequently, the functional integrity of the bones, in terms of load bearing and haematopoiesis, is compromised. Csf1 op/op mice survive to adulthood because of extra-medullary haematopoiesis in the spleen and liver 19 , and as mice age, osteoclastogenesis is rescued by compensatory expression of VEGF and therefore bone marrow haematopoiesis commences 20 .
Remodelling deficiencies in the absence of macrophages have also been noted in several other tissues, including the mammary gland, kidney and pancreas, suggesting a general requirement for macrophages in tissue patterning and branching morphogenesis 19, 26 . In the mammary gland, the best studied of these tissues, macrophages are recruited to the growing ductal structure and their loss results in a slower rate of outgrowth and limited branching, phenotypes that are reiterated during the mammary growth caused by pregnancy 19 . This stems partly from the failure to remodel the extracellular matrix during the outgrowth of the ductal structures. However, recent studies have also implicated macrophages in maintaining the viability and function of mammary stem cells, which reside at the tip of the duct known as the terminal end bud and are responsible for the outgrowth of this structure 27 . In stem cell biology similar roles for macrophages have been suggested in the maintenance of intestinal integrity and its regeneration after damage 28 , whereas a subpopulation of macrophages in the haematopoietic niche regulates the dynamics of haematopoietic stem cell release and differentiation 29 . Furthermore, in regenerating livers, macrophages specify hepatic progenitor fate through the expression of WNT ligands and antagonism of Notch signalling 30 . Macrophage control of stem cell function is clearly an emerging and important research area.
As 'professional' phagocytes (macrophages were originally defined by their exceptional phagocytic ability), macrophages perform critical functions in the remodelling of tissues, both during development and in the adult animal; for example, during erythropoiesis, maturing erythroblasts are surrounded by macrophages that ingest the extruded erythrocyte nuclei. Remarkably, this function of macrophages is critical because in its absence, erythropoiesis is blocked and lethality ensues 31 . Macrophages also make decisions about haematopoietic egress from the bone marrow through engulfing cells that do not express the CD47 ligand 32 . They also maintain the haematopoietic steady state through engulfment of neutrophils and erythrocytes in the spleen and liver, and the failure of this activity results in neutropenia, splenomegaly and reduced body weight 33 . Phagocytosis, particularly of apoptotic cells, is clearly central to macrophage function and this is emphasized by the build-up in macrophage-depleted mice of such cells during development; for example, during the resolution of the inter-digit areas during limb formation 34 . However, there is no apparent consequence to this phenomenon, as less-efficient 'non-professional' phagocytes clear excess apoptotic cells. Despite this, macrophages have evolved to 'eat' cells, and to suppress inflammation and autoimmunity in response to self-antigens that may arise during homeostasis 35 . Macrophages also regulate angiogenesis through a number of mechanisms. This has been most extensively studied in the eye during its development. Early in the postnatal period, during regression of the hyaloid vasculature, macrophages identify and instruct vascular endothelial cells to undergo apoptosis if these cells do not receive a counterbalancing signal from pericytes to survive. WNT7B that is synthesized by macrophages delivers this cell-death signal to the vascular endothelial cells, and in the absence of either WNT7B or macrophages there is vascular over-growth 36 . WNT secretion is also required later in retinal vasculature development but in this case macrophage synthesized WNT5A and WNT11, a non-canonical WNT, induces expression of soluble VEGF receptor 1 (VEGFR1) through an autocrine mechanism that titrates VEGF and thereby reduces vascular complexity so that the vascular system is appropriately patterned 37 . Furthermore, at other times of ocular development, macrophages regulate vascular complexity. In this circumstance, macrophage-synthesized VEGFC reinforces Notch signalling 38 . In addition, during angiogenesis in the hindbrain, macrophages enhance the anastomosis of tip and stalk cells to give functional vessels 39 . These macrophage functions are not restricted to the vascular arm of the circulatory system, as they also have roles in lymphangiogenesis during development 40 , and in adults they have a notable role in maintaining fluid balance through their synthesis of VEGFC 41 . Brain development is also influenced by macrophages. These macrophages called microglia depend on CSF1R signalling for their presence 10, 16 .
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In the absence of this signalling there are no microglia, and the brains of these mice have substantial structural defects as they mature 16 . Both CSF1 and IL-34 are expressed by neurons in a mutually restricted pattern of expression, and IL-34 is the major factor for microglial differentiation and viability 10, 42 . The disruption of architecture in the brain of the Csf1r-null mouse, together with well-documented deficiencies in neuronal processing regulating olfaction and the reproductive axis in the hypothalamus in Csf1-null mice, strongly suggests that microglia are involved in the development of neuronal circuitry and the maintenance of brain structure 16, 19 . Indeed, microglia have been shown to promote neuron viability 19 , modulate neuronal activity 43 and prune synapses during development 44 , as well as express a range of neuronal growth and survival factors, including NGF 19 . This conjecture is supported by the finding that hypomorphic mutation in CSF1R in humans is responsible for hereditary diffuse leukoencephalopathy with spheroids that results from loss of myelin sheaves and axonal destruction 45 . These trophic activities of microglia are also consistent with macrophages having roles in neuroprotection after injury, as defined in a variety of models. These effects include the promotion of survival and proliferation of retinal progenitor cells, and the regeneration of adult sensory neurons [46] [47] [48] . However, caution needs to be exercised in attributing all of the phenotypes observed in the brains of Csf1r-mutant mice or humans to the loss of microglia, as Csf1r expression has been reported on neuronal stem cells and their development in vivo is regulated by CSF1R 42 . Nevertheless, it seems likely that microglia have important roles in the development of neuronal circuitry, though their effects on the proliferation, survival and connectivity of neurons 43 , through their effects on myelination, or by modulating angiogenesis and fluid balance in the brain 16 . The examples given above indicate a few of the roles for macrophages in normal development and these are likely to expand with further study. Phenotypically in mice, macrophages are CD11b
1 and phagocytic and their activities are through the temporal and spatial delivery of developmentally important molecules such VEGFs and WNTs as well as proteases. These developmental roles of macrophages are re-capitulated in repair as described below but are also intimately involved in chronic conditions that lead to pathologies as well as the development and progression of malignancies.
Macrophages in metabolic homeostasis
Mammalian metabolic organs, such as the liver, pancreas and adipose tissue, are composed of parenchymal and stromal cells, including macrophages, which function together to maintain metabolic homeostasis 49 . By regulating this interaction, mammals are able to make marked adaptations to changes in their environment and in nutrient availability. For example, during bacterial infection, innate activation of macrophages results in secretion of pro-inflammatory cytokines, such as TNF-a, IL-6 and IL-1b, which collectively promote peripheral insulin resistance to decrease nutrient storage 50, 51 . This metabolic adaptation is necessary for mounting an effective defence against bacterial and viral pathogens because nearly all activated immune cells preferentially use glycolysis to fuel their functions in host defence. However, this adaptive strategy of nutrient re-allocation becomes maladaptive in the setting of diet-induced obesity, a state that is characterized by chronic low-grade macrophagemediated inflammation 51, 52 . In the sections below, we provide a general framework for understanding the pleiotropic functions carried out by macrophages to maintain metabolic homeostasis (Fig. 3 ). Although our current knowledge in this area is primarily derived from studies in obese insulin-resistant mice, it is likely that tissue-resident macrophages also participate in facilitating metabolic adaptations in healthy animals.
White adipose tissue
White adipose tissue (WAT) is not only the principal site for long-term storage of nutrients but also regulates systemic metabolism through the release of hormones called adipokines 53 . These metabolic functions of WAT are primarily performed by adipocytes with trophic support provided by stromal cells, including macrophages. Thus, macrophage representation in WAT, both in terms of numbers and their activation state, reflects the metabolic health of adipocytes 51 . For example, in lean healthy animals, adipose tissue macrophages comprise 10-15% of stromal cells and express the canonical markers (Arg1
of AAMs 54 . In contrast, macrophage content increases to 45-60% during obesity 55, 56 , resulting from increased recruitment of Ly6C hi monocytes that differentiate into inflammatory macrophages, as judged by their expression of Nos2, Tnfa (also known as Tnf) and Itgax 54, 55 . Although these macrophages contribute to the development of insulin resistance in adipocytes, recent studies suggest that these cells also participate in remodelling of the enlarging WAT, functions that facilitate the storage of excess nutrients in adipocytes 57 . This suggests that two macrophage subsets coordinate homeostatic adaptations in adipocytes of lean and obese animals.
In healthy animals, AAMs are critical for maintaining insulin sensitivity in adipocytes 51 . This trophic effect of AAMs is partly mediated by secretion of IL-10, which potentiates insulin action in adipocytes 54 . These observations led various groups to focus on cell-intrinsic and cell-extrinsic mechanisms that control alternative activation of adipose tissue macrophages. For cell-intrinsic factors, transcription factors downstream of IL-4 and IL-13 signalling, such as PPAR-c, PPAR-d and KLF4, were found to be required for the maintenance of AAMs in WAT and metabolic homeostasis [58] [59] [60] [61] . The dominant cell-extrinsic factors regulating maturation of AAMs in lean WAT are the type 2 cytokines IL-4 and IL-13 (ref. 60). Absence of eosinophils, which constitute the major cell type capable of IL-4 secretion in WAT 62 , impairs alternative activation of adipose tissue macrophages and makes mice susceptible to obesity-induced insulin resistance. Together, these reports have established that homeostatic functions performed by AAMs in WAT are required for metabolic adaptations to excessive nutrient intake.
Although adipocytes in lean animals can easily accommodate acute changes in energy intake, chronic increase in energy intake places adipocytes under considerable metabolic stress. Consequently, the enlarging WAT releases chemokines, such as CC-chemokine ligand 2 (CCL2), CCL5 and CCL8, to recruit Ly6C hi inflammatory monocytes into the WAT 63 , where these cells differentiate into CD11c 1 macrophages and form 'crown-like structures' around dead adipocytes 54, 64 . As these CD11c 1 macrophages phagocytize dead adipocytes and become lipid engorged, they initiate expression of inflammatory cytokines, such as TNF-a and IL-6, which promote insulin resistance in the surrounding adipocytes 54 . Presumably, this initial decrease in adipocyte insulin sensitivity is an adaptation to limit nutrient storage. However, in the setting of unabated increase in caloric intake, this adaptive response becomes maladaptive, contributing to pathogenesis of obesity-induced systemic insulin resistance.
Brown adipose tissue
In mammals, brown adipose tissue (BAT) is the primary thermogenic organ that is activated by exposure to environmental cold 65 . For decades, it had been thought that hypothalamic sensing of cold triggers an increase in sympathetic nerve activity to stimulate the BAT program of adaptive thermogenesis 65 . However, recent work has demonstrated that resident macrophages are required to facilitate the metabolic adaptations of BAT and WAT to cold. Specifically, exposure to cold temperatures results in alternative activation of BAT and WAT macrophages, which are required for induction of thermogenic genes in BAT and lipolysis of stored triglycerides in WAT 66 . Accordingly, mice lacking AAMs are unable to mobilize fatty acids from WAT to maximally support BAT thermogenesis, which is necessary for the maintenance of core body temperature in cold environments. These supportive functions of macrophages are mediated by their secretion of norepinephrine, which surprisingly accounts for approximately 50% of the catecholamine content of BAT and WAT in the cold. Thus, cold-induced alternative activation of BAT and WAT macrophages provides an example of how resident macrophages provide trophic support to facilitate the RESEARCH REVIEW function of tissue parenchymal cells, in this case the white and brown adipocytes.
Liver and pancreas
Liver integrates nutrient, hormonal and environmental signals to maintain glucose and lipid homeostasis in mammals. Over the past few years, evidence has emerged that Kupffer cells, the resident macrophages of liver, facilitate the metabolic adaptations of hepatocytes during increased caloric intake. During obesity, an imbalance between the uptake, synthesis and oxidation of fatty acids results in increased lipid storage in hepatocytes, a key factor in the development of hepatic insulin resistance 67 . Interestingly, Kupffer cells directly participate in this process by regulating the oxidation of fatty acids in hepatocytes. An early insight into this process came from studies that identified PPAR-d as an important regulator of the IL-4-and IL-13-driven program of alternative macrophage activation 58, 61 . These studies revealed that loss of PPAR-d in myeloid cells specifically impaired alternative activation of Kupffer cells, resulting in hepatic steatosis and insulin resistance. A similar phenotype was observed when Kupffer cells were depleted in rodents using gadolinium chloride or clodronate-containing liposomes 68 Although the precise factors elaborated by Kupffer cells are still not known, co-culture studies suggest that Kupffer-cell-derived factors work in a trans-acting manner to maintain hepatic lipid homeostasis 58, 61 . Pancreas functions as an endocrine and exocrine gland in mammals. Recent findings suggest that, analogous to obesity-induced WAT inflammation, high-fat feeding induces the infiltration of macrophages into the insulin-producing islets. In this case, the increased intake of dietary lipids results in beta-cell dysfunction, which induces the expression of chemokines, such as CCL2 and CXCL1, to recruit inflammatory monocytes or macrophages into the islets 69, 70 . Consequently, the secretion of IL-1b and TNF-a by the infiltrating macrophages augments beta-cell dysfunction, resulting in impaired insulin secretion and hyperglycaemia in obese mice. Although these reports have elucidated the pathogenic role of macrophages in beta-cell dysfunction, in the future it will be important to determine whether macrophages also participate in the physiological regulation of beta-cell biology as they do during development and pregnancy 19 .
Macrophages in disease
When tissues are damaged following infection or injury, inflammatory monocytes (Ly6c 1 in mice) are recruited from the circulation and differentiate into macrophages as they migrate into the affected tissues 4 . These recruited macrophages often show a pro-inflammatory phenotype in the early stages of a wound-healing response. They secrete a variety of inflammatory mediators, including TNF-a, IL-1 and nitric oxide, which activate anti-microbial defence mechanisms, including oxidative processes that contribute to the killing of invading organisms 7 . They also produce IL-12 and IL-23, which direct the differentiation and expansion of anti-microbial T H 1 and T H 17 cells (T helper cells that express IFN-c and IL-17) that help to drive inflammatory responses forward 3 . Although these inflammatory macrophages are initially beneficial because they facilitate the clearance of invading organisms, they also trigger substantial collateral tissue damage because of the toxic activity of reactive oxygen and nitrogen species and of T H 1 and T H 17 cells 71 . Indeed, if the inflammatory macrophage response is not quickly controlled, it can become pathogenic and contribute to disease progression, as is seen in many chronic inflammatory and autoimmune diseases 72, 73 . To counteract the tissue-damaging potential of the inflammatory macrophage response, macrophages undergo apoptosis or switch into an anti-inflammatory or suppressive phenotype that dampens the proinflammatory response while facilitating wound healing 7 . These regulatory macrophages often produce ligands associated with development, regulate insulin sensitivity in obesity. In lean healthy animals, adipose tissue macrophages comprise 10-15% of stromal cells, and express markers that link them with AAMs, which are critical for maintaining insulin sensitivity in adipocytes, partly through the production of IL-10. Type 2 cytokines such as IL-4 and IL-13, which are derived from a variety of cellular sources, including eosinophils, seem to be important for the maintenance of the AAM phenotype in lean tissues. In contrast, during obesity, Ly6c hi monocytes are recruited, which increases macrophage content to 45-60%. These macrophages, in contrast to normal resident macrophages, express an inflammatory phenotype, characterized by the production of TNF-a, IL-6 and IL-1b. These inflammatory macrophages decrease insulin sensitivity while facilitating the storage of excess nutrients. The enlarging white adipose tissues in turn release chemokines, such as CCL2, CCCL5 and CCL8, to recruit additional Ly6c hi inflammatory monocytes that exacerbate the process. This mechanism is also enhanced during bacterial and viral infections, so essential nutrients are diverted to lymphocytes, which must use glycolysis to enhance their activation at times of stress. CAM, classically activated macrophage. Eos, eosinophils; ILC2, type 2 innate lymphoid cells; Mono, monocytes.
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such as WNT ligands, that are essential for tissue repair 74 . It is becoming increasingly clear that the mechanisms that regulate the transformation of inflammatory macrophages into an anti-inflammatory cell or suppressive macrophages back into a pro-inflammatory phenotype has a major impact on the progression and resolution of many chronic diseases, as discussed below (Fig. 4) .
Macrophages in cancer
Tumours are abundantly populated by macrophages 3 . Although macrophages were originally thought to be part of an anti-tumour response, clinical and experimental data indicate that in the large majority of cases macrophages promote tumour initiation, progression and metastasis 75 . In response to persistent infections or chronic irritation, macrophages synthesize inflammatory cytokines, IFN-c, TNF-a and IL-6, which engage other immune cells to sustain the chronic inflammation that seems to be causal in tumour initiation and promotion 76 . The tumourinducing activities are multi-factorial; for example, through the production of inflammatory cytokines, such as IFN-c in skin cancer that is induced by exposure to ultraviolet light 77 and TNF-a in carcinogeninduced cancer, through the generation of a mutagenic environment 76, 78 or through alterations of the microbiome 79 . However, once tumours become established they cause differentiation so that the tumour-associated macrophages (TAMs) change from an immunologically active state to adopt a trophic immunosuppressive phenotype that promotes tumour progression and malignancy (they become 'tumour-educated') 75 . In established tumours, TAMs stimulate tumour-cell migration, invasion and intravasation, as well as the angiogenic response required for tumour growth 75, 80, 81 . These events are required for tumour cells to become metastatic, as they facilitate their escape into the circulatory or lymphatic system. Evidence from autochthonous models of breast cancer suggests that the macrophages take on these activities in response to CSF1, IL-4 and IL-13 encountered in the tumour microenvironment. For example, IL-4-mediated differentiation 80 results in a reciprocal paracrine dialogue between CSF1 and EGF, synthesized by tumour cells and TAMs, respectively, that promotes tumour-cell invasion and intravasation in mammary cancer 82 . In mammary cancers, this loop is initiated by CXCL12 in the polyoma virus middle T (PyMT) model or heregulin (also known as pro-neuregulin-1, membrane-bound isoform) in the HER2/Neu model. In human xenograft models, CCL18 is also required for tumour-cell invasion and metastasis, because it has a role in triggering integrin clustering 83 . TAMs also remodel the tumour microenvironment through the expression of proteases such as matrix metalloproteinases (MMPs), cathepsins and urokinase plasminogen activator, and matrix remodelling enzymes such as lysyl oxidase and SPARC 81, 84 . The proteases, such as cathepsin B, MMP2, MMP7 and MMP9, cleave extracellular matrix and thereby provide conduits for the tumour cells and release growth factors such as heparin-binding EGF (HB-EGF) and EGF mimics that foster tumour-cell invasion and metastasis 84, 85 . Macrophages have an important role in tumour angiogenesis as they regulate the marked increase in vascular density, known as the angiogenic switch, that is required for the transition to the malignant state 86 . These angiogenic TAMs are characterized by the expression of the angiopoietin receptor TIE2, which is also expressed in macrophages during development 87, 88 . Ablation of this specific population inhibits tumour angiogenesis and thus tumour growth and metastasis in a variety of models 87, 88 . TAMs secrete many angiogenic molecules, including VEGF family members TNF-a, IL-1b, IL-8, PDGF and FGF 75, 88, 89 . Of these, myeloid-derived VEGF is required for the angiogenic switch 89 but other aspects of angiogenesis can be independent of VEGF and involve the secreted protein Bv8 (also known as prokineticin 2 or During pathogen invasion or after tissue injury or exposure to environmental irritants, local tissue macrophages often adopt an activated or 'inflammatory phenotype'. These cells are commonly called classically activated macrophages (CAMs), because they were the first activated macrophage population to be formally defined. These macrophages are activated by IFN-c and/or after TLR engagement, leading to the activation of the NF-kB and STAT1 signalling pathways. This in turn increases the production of reactive oxygen and nitrogen species, and proinflammatory cytokines, like TNF-a, IL-1 and IL-6, that enhance antimicrobial and anti-tumour immunity, but may also contribute to the development of insulin resistance and diet-induced obesity. In contrast, some epithelium-derived alarmins and the type 2 cytokines IL-4 and IL-13 result in an 'alternative' state of macrophage activation (AAMs) that has been associated with wound healing, fibrosis, insulin sensitivity and immunoregulatory functions. They also activate wound-healing, pro-angiogenic and pro-fibrotic macrophages (PFMs) that express TGF-b1, PDGF, VEGF, WNT ligands, and various matrix metalloproteinases that regulate myofibroblast activation and the deposition of extracellular matrix components. AAMs also express a variety of immunoregulatory proteins, like arginase 1 (ARG1), RELMa, PDL2 and IL-10 that regulate the magnitude and duration of immune responses. These cells also scavenge collagen and extracellular matrix components, and thus the ECM is remodelled. Therefore, in contrast to CAMs that activate immune defenses, AAMs are typically involved in the suppression of immunity and reestablishment of homeostasis. They suppress obesity and insulin resistance that result from the sustained activity of the CAM macrophages. Although type 2 cytokines are important inducers of suppressive or immunoregulatory macrophages, it is now clear that several additional mechanisms can also contribute to the activation of macrophages with immunoregulatory activity. Indeed, IL-10-producing regulatory T (T reg ) cells, Fcc receptor engagement, engulfment of apoptotic cells, and prostaglandins have also been shown to preferentially increase the numbers of regulatory macrophages (M reg ) that suppress inflammation and inhibit anti-microbial and anti-tumour defences. The tumour microenvironment itself also promotes the recruitment and activation of immune inhibitory cells, including those of the mononuclear phagocytic series, such as myeloid-derived suppressor cells (MDSCs), tumourinfiltrating macrophages (TIMs), TIE2-expressing macrophages (TEMs), tumour-associated macrophages (TAMs) and metastasis-associated macrophages (MAMs) that promote angiogenesis and tumour growth while suppressing anti-tumour immunity. CTL, cytotoxic T lymphocyte; Neu, neutrophils; NK, natural killer cells; ROS, reactive oxygen species; TSLP, thymic stromal lymphopoietin.
RESEARCH REVIEW PROK2) 90 . Angiogenic macrophages can be recruited to the tumours by hypoxia 88, 91 but also by growth factors such as CSF1 and VEGF 92 . Tumours have a proclivity to metastasize to particular sites, and this phenotype is partially defined by macrophages. Data suggest that the tumour-produced fragments of ECM molecules or exosomes prepare these sites, known as pre-metastatic niches, to be receptive to the circulating tumour cells through recruitment of myeloid cells characterized by CD11b and VEGFR1 positivity 93, 94 . These niches are tumour-typedependent and the fate of the tumour cells can be reprogrammed to a different tissue by the transfer of tumour-conditioned serum to a naive mouse strain 93 . These niches are also dependent on coagulation as this is necessary for recruitment of the myeloid cells that have recently been more precisely defined as F4/80
1 monocytes (or F4/80 1 macrophages) 95 . At lung metastatic sites, mini-clots form that enable the arrest of tumour cells 95 that then produce CCL2 to recruit CCR2 1 Ly6c 1 inflammatory monocytes that rapidly develop into Ly6c -metastasisassociated macrophages (MAMs) 96 . These monocytes and MAMs promote tumour-cell extravasation, partly through their expression of VEGF, which induces local vascular permeability. MAMs that are intimately associated with the tumour cells also promote their viability through clustering of tumour-cell-expressed VECAM1 that interlocks with the MAM expressed counter receptor integrin a4 (ref. 83) . MAMs also promote subsequent growth of the metastatic cells and, importantly, ablation of these cells after the metastases are established inhibits metastatic growth 75 . In mice, these individual pro-tumoral functions are carried out by different subpopulations, although they all express canonical markers such as CD11b, F4/80 and CSF1R 75 . This view is consistent with recent profiling of immune cells in various tumour types in mice and humans that indicates that there are differences in the extent of macrophage infiltration and in phenotype 97 . For example, detailed phenotypic profiling in human hepatocellular carcinoma shows various macrophage subtypes defined by specific location that have both pro-and anti-tumoral properties through their engagement of the acquired immune system, although overall the balance is tilted towards pro-tumoral functions 98 . Transcriptional profiling of TAM subpopulations in mice suggest they more closely resemble embryonic macrophages than inflammatory ones, as they have higher expression of developmentally relevant molecules, such as those of the WNT pathway 75 . This strongly suggests that the trophic roles of macrophages found during development, in metabolism and in the maintenance of homeostasis, are subverted by tumours to enhance their growth, invasion and complexity. However, transcriptional control of these different phenotypes is only just being revealed, particularly in in vivo contexts 3 . Many studies have analysed macrophage responses to LPS signalling through nuclear factor-kB (NF-kB), but this results in 'activated' macrophages that are mainly involved in antibacterial responses and are likely to be anti-tumoral 23 . In contrast, in their trophic and immunosuppressive functions, TAMs are shaped by IL-10 and IL-4 or IL-13 that signal to STAT3 and STAT6, respectively 3, 99 . The PARP proteins and KLF4 also co-operate to induce a pattern of gene expression associated with their tumour-promoting phenotype 3 . In macrophages, CSF1R also signals to a wide range of transcriptional factors, including MYC and FOS 15 . MYC signalling has been shown to be important for pro-tumoral phenotypes 100 . CSF1R expression is regulated in turn by ETS2 transcription factors, and genetic ablation of this factor in macrophages in PyMT tumours recapitulates the loss of CSF1 in tumours, as angiogenesis is inhibited and tumour growth decreases 101 .
To study the interaction of these factors and other regulatory molecules such as microRNAs and epigenetic controls 3 will require sophisticated genomic analyses that will help to differentiate the regulation of the multiple subsets 23 . These functions and other regulatory systems have been reviewed recently 3 .
Macrophages in inflammatory disease
Macrophages have important roles in many chronic diseases, including atherosclerosis, asthma, inflammatory bowel disease, rheumatoid arthritis and fibrosis 7, [102] [103] [104] . Their contributions to these diseases vary greatly in different stages of disease and are controlled by many factors. For example, allergic asthma is a complex chronic inflammatory disease of the lung defined by airway inflammation, airway obstruction, airway hyper-responsiveness and pathological lung remodelling. The inflammatory response is characterized by the recruitment of T H 2 lymphocytes, mast cells, eosinophils and macrophages to the lung, and by elevated expression of allergen-specific immunoglobulin-E (IgE) in the serum. It has been suggested that the chronicity of type 2 cytokine-mediated airway inflammation that is characteristic of allergic asthma is explained by the presence of a macrophage-like antigen-presenting cell population that persists in the airway lumen 105 . Pulmonary macrophages produce a variety of factors that directly stimulate airway smooth-muscle contractility and degradation of the ECM that contributes to pathological airway remodelling. Airway macrophages from some asthmatics are bathed in type-2-associated cytokines, including IL-4, IL-13 and IL-33, causing their differentiation, which has been implicated in the pathogenesis of asthma 2 . These macrophages in turn promote the production of type 2 cytokines by pulmonary CD4 T lymphocytes, and produce a variety of cytokines and chemokines that regulate the recruitment of eosinophils, T H 2 cells and basophils to the lung, suggesting a viscous cycle that worsens disease 7 . Adoptive transfer studies have shown that the severity of allergen-induced disease is exacerbated by IL-4R
1 macrophages 106 , whereas protection from allergic airway disease is associated with a reduction in IL-4R
1 macrophages in some studies 107 .
Increased numbers of IL-4R
1 macrophages have also been reported in the lungs of asthmatic patients that have reduced lung function 108 . Nevertheless, studies conducted with LysM cre IL-4Ra -/lox mice in which Cre-mediated recombination results in deletion of the IL-4Ra chain in the myeloid cell lineage identified no substantial role for IL-4Ra-activated macrophages in ovalbumin-and house-dust-mite-induced allergic airway disease 109 .
Macrophages have also been implicated in the pathogenesis of a variety of autoimmune disease, including rheumatoid arthritis, multiple sclerosis and inflammatory bowel diseases. In these diseases, macrophages are an important source of many of the key inflammatory cytokines that have been identified as drivers of autoimmune inflammation, including IL-12, IL-18, IL-23 and TNF-a 110 . Macrophage-derived IL-23 promotes end-stage joint autoimmune inflammation in mice. TNF-a also functions as an important driver of chronic polyarthritis, whereas IFN-c-and TNF-a-dependent arthritis in mice has been attributed to macrophages and dendritic cells that produce IL-18 and IL-12. The pathogenesis of chronic demyelinating diseases of the central nervous system (CNS) has also been attributed to macrophages that display a proinflammatory phenotype. These inflammatory macrophages contribute to axon demyelination in experimental autoimmune encephalomyelitis in mice, a frequently used model of multiple sclerosis. Consequently, novel therapeutic strategies that target specific myeloid cell populations could help to ameliorate pathogenic inflammation in the CNS 111 . The pathogenesis of inflammatory bowel disease is also tightly regulated by inflammatory macrophages. A subset of TLR2
1 macrophages has been shown to promote colonic inflammation by producing TNF-a 112 . A recent study showed that inflammatory mediators produced in the colon convert homeostatic antiinflammatory macrophages into pro-inflammatory dendritic-cell-like cells that are capable of producing large quantities of IL-12, IL-23, inducible nitric oxides synthase and TNF-a 113 . CD14
1 macrophages that produce IL-23 and TNF-a have also been identified in Crohn's disease patients 103 . Thus, macrophages and dendritic cells are key producers of many of the cytokines that have been implicated in the pathogenesis of inflammatory bowel disease.
Although there is substantial evidence to support the idea that inflammatory macrophages have roles in autoimmune inflammation, many studies have also reported suppressive roles for macrophages. For example, macrophages that produce reactive oxygen species can protect mice from arthritis by inhibiting T-cell activation 114 . Pro-inflammatory cytokines that are produced by activated macrophages have also been
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shown to protect mice from Crohn's disease by facilitating the clearance of pathogenic commensal bacteria from the mucosal lining of the bowel 115 . Recruited monocytes and resident tissue macrophages are also thought to maintain homeostasis in the intestine by clearing apoptotic cells and debris, promoting epithelial repair, antagonizing pro-inflammatory macrophages, and by producing the suppressive cytokine IL-10, which is critical for the maintenance of FOXP3 expression in colonic regulatory T cells (T reg cells) 113, 115, 116 . Macrophages also protect rodents from demyelinating diseases of the CNS by promoting T-cell apoptosis and by expressing the anti-inflammatory cytokines TGF-b1 and IL-10. The inhibitory receptor CD200 (also known as OX2), which is also expressed on antiinflammatory macrophages, has been shown to prevent the onset of experimental autoimmune encephalomyelitis in mice 117 . A unique population of monocyte-derived macrophages also reduces inflammation resulting from spinal cord injury, providing further evidence of a protective role for macrophages in the CNS 118 . Together, these observations show how changes in macrophage differentiation in the local environment can have a decisive role in the pathogenesis of a wide variety of autoimmune and inflammatory diseases.
Macrophages in fibrosis
Although macrophages phagocytose and clear apoptotic cells as a part of their normal homeostatic function in tissues, when they encounter invading organisms or necrotic debris after injury, they become activated by endogenous dangers signals and pathogen-associated molecular patterns. These activated macrophages produce anti-microbial mediators, like reactive oxygen and nitrogen species and proteinases, that help to kill invading pathogens and thus assist in the restoration of tissue homeostasis. However, they also produce a variety of inflammatory cytokines and chemokines such as TNF-a, IL-1, IL-6 and CCL2 that help to drive inflammatory and anti-microbial responses forward 8, 72 . This exacerbates tissue injury and in some cases leads to aberrant wound healing and ultimately fibrosis (scarring) if the response is not adequately controlled, as has been demonstrated by the selective depletion of macrophages at various stages of the wound-healing response 119 . Therefore, in recent years research has focused on elucidating the mechanisms that suppress inflammation and prevent the development of fibrosis. Although most wound-healing responses are self-limiting once the tissue-damaging irritant is removed, in many chronic fibrotic diseases the irritant is either unknown or cannot be eliminated easily 120 . In this situation, it is crucial that the dominant macrophage population converts from one exhibiting a pro-inflammatory phenotype to one exhibiting anti-inflammatory, suppressive or regulatory characteristics so that collateral tissue damage is kept at a minimum (Fig. 4) . A variety of mediators and mechanisms have been shown to regulate this conversion, including the cytokines IL-4 and IL-13, Fcc receptor and TLR signalling, the purine nucleoside adenosine and A2A receptor signalling, prostaglandins, T reg cells, and B1 B cells 120, 121 . Each of these mediators has been shown to activate distinct populations of macrophages with suppressive or regulatory characteristics. These 'regulatory' macrophages express a variety of soluble mediators, signalling intermediates and cell-surface receptors, including IL-10, arginase 1, IKKa, MMP13, maresins, CD200, RELMa and PD-L2, which have all been shown to decrease the magnitude and/or duration of inflammatory responses, and in some cases to contribute to the resolution of fibrosis 7 . They also produce a variety of soluble mediators, including CSF1, insulinlike growth factor 1, and VEGF, that promote wound healing 122 . Consequently, in addition to promoting fibrosis, macrophages are intimately involved in the recovery phase of fibrosis by inducing ECM degradation, phagocytizing apoptotic myofibroblasts and cellular debris, and by dampening the immune response that contributes to tissue injury 120 . Therefore, current fibrosis research is focused on characterizing these regulatory macrophage populations and devising therapeutics strategies that can exploit their anti-inflammatory, anti-fibrotic and woundhealing properties.
Perspectives
Our understanding of macrophage biology is increasing rapidly, and it is now understood that they have diverse origins, transcriptional complexity and lability, and are capable of phenotypic switching in accordance with homeostatic demands and in response to insult. Macrophages are involved in almost every disease and represent attractive therapeutic targets because their function can be augmented or inhibited to alter disease outcome. However, for these therapies to be effective it is necessary to understand macrophage diversity and define their phenotypes according to anatomical location and function, and according to the regulation of the particular set-points that define the recognizable macrophages, such as microglia, osteoclasts and Kuppffer cells. Indeed, the recognition of multiple origins (yolk sac, fetal liver, bone marrow) may result in the conclusion that there is no such thing as a 'macrophage' but instead, clades of cells that have similar characteristics but different origins. Their different origins may in fact provide unique opportunities to target the recruited monocytes and macrophages selectively in the context of the chronic diseases discussed above, thereby inhibiting the pathology without disturbing resident macrophages and thereby maintaining normal homeostasis. To define these similarities and differences it will be necessary to determine proteomes and transcriptomes of particular subtypes; this was recently performed for resident macrophages 1 . The field of genomic analysis is advancing rapidly and will provide unique insights and novel methods to define macrophage types. Furthermore, macrophage biology in humans is poorly developed because of the technical limitations of obtaining fresh material for fluorescence-associated cell sorting (FACS) and the over-reliance of functional and genomic studies on cell lines such as the myelomonocytic leukaemic cell line THP1 (ref. 123) or the in vitro differentiation of circulating monocytes by CSF1. Notable differences also exist between human and mouse macrophages; for example, the inability of human macrophages to increase arginase 1 expression that is an important marker of IL-4-regulated macrophages in mice 3 . These differences mean that the binary classifications such as M1 and M2 are inadequate. Human macrophage diversity has begun to be defined 124 ; several sequencing efforts are in progress and these will begin to address the essential need to translate mouse biology into the human context.
Considerable advances in our knowledge of macrophage biology have been made recently using mouse genetic approaches. For example, macrophages can be fluorescently labelled by expressing GFP from the Csf1r promoter, and this is used to identify and, in some cases, record live images of them using intravital microscopy 23, 125 . Furthermore, the development of macrophage-restricted Cre recombinases-for example, expressed from the LysM or Csf1r promoters-and the ability to ablate macrophages through the expression of the diptheria toxin receptor, which sensitizes mouse cells to the toxic effect of diptheria toxin 119 , or using miRNAs to direct the expression of herpes simplex virus thymidine kinase in macrophages, have been key to defining the functions of macrophages. Although these systems have provided notable insights into macrophage function, none of the promoters is uniquely expressed in macrophages, and they are also expressed in most macrophage types, thereby making it difficult to discriminate the functions of subclasses of macrophages. In the future, specific promoters will be developed to ablate genes in particular subsets, more sophisticated lineage tracing will make it possible to follow cell fates, and subtype switching will be possible through photo-activatable flours such as Dendra2 that enable a single cell, or a few cells, to be tracked 125 . Therapeutic targeting of macrophages is now in progress 21, 23 . Most of the therapies are targeted at pan-macrophage markers such as CSF1R. In the case of CSF1R reagents, including small molecules and monoclonal antibodies that inhibit the ligand, ligand binding or tyrosine kinase activity of the receptor are at various stages of clinical trials for the treatment of cancer 21 . Other strategies in fibrosis and cancer have been to target the recruitment of macrophages, particularly through inhibition of inflammatory monocyte trafficking with anti-CCL2 or -CCR2 antibodies. In one example, the protective effects of recombinant human RESEARCH REVIEW serum amyloid P (also known as pentraxin 2) in idiopathic pulmonary fibrosis and post-surgical scarring in patients treated for glaucoma are thought to occur through the reduction of inflammation and fibrosis resulting from the induction of IL-10 production in regulatory macrophages 107 . Neutralization of GM-CSF using antibodies is being tested in phase II trials for multiple sclerosis and rheumatoid arthritis 21 . In the future, it seems that it will be possible to exploit the inherent plasticity of macrophages to adjust their set points to control obesity by downmodulating inflammatory cytokines, to resolve fibrosis by inducing the differentiation of resolving macrophages, and to treat cancer by converting macrophages from their trophic to an immunologically activated anti-tumoral state.
